midostaurin (RYDAPT°) for some types of acute myeloid leukaemia

Improved survival, but adverse effects underestimated

Abstract

- The standard treatment for patients with acute myeloid leukaemia is a combination of daunorubicin + cytarabine as induction therapy, followed by consolidation therapy with chemotherapy or bone marrow transplantation. Maintenance therapy has not been shown to be of benefit in prolonging survival. About one-third of patients have tumour cells carrying a mutation in the FLT3 gene, which is an adverse prognostic factor.

- Midostaurin (Rydapt®, Novartis) is an inhibitor of multiple tyrosine kinases, including the FLT3 kinase. It has been authorised in the European Union for patients with newly diagnosed acute myeloid leukaemia who carry a FLT3 mutation.

- In a randomised, double-blind, placebo-controlled trial in 717 patients aged less than 60 years, addition of midostaurin to the daunorubicin + cytarabine combination in the induction phase, then to high-dose cytarabine in the consolidation phase, with continuation of midostaurin in a maintenance phase, increased the proportion of patients alive at 5 years to 51% compared to 43%. However, midostaurin was not evaluated in patients aged over 60 years, who generally have a poor prognosis.

- Assessment of the adverse effects of midostaurin in the main trial was incomplete. According to available data, midostaurin carries at least a risk of gastrointestinal disorders, catheter infections, lymphopenia and elevated liver transaminase levels.

- Midostaurin is metabolised by cytochrome P450 isoenzyme CYP 3A4 and may be an inducer of various cytochrome P450 isoenzymes and an inhibitor of P-glycoprotein, creating the potential for numerous pharmacokinetic interactions. Additive adverse effects with drugs causing gastrointestinal or hepatic disorders and lymphopenia can also be expected.

- Midostaurin is toxic to the embryo and fetus.

OFFERS AN ADVANTAGE

In a trial in 717 patients with acute myeloid leukaemia and a FLT3 mutation, midostaurin (a multi-tyrosine kinase inhibitor) added to induction and consolidation therapy, and then continued as maintenance monotherapy, increased the proportion of patients alive at 5 years by 8%. It was not evaluated in patients aged over 60 years, who generally have a worse prognosis. According to an incomplete assessment of its adverse effects, midostaurin mainly carries a risk of gastrointestinal disorders, elevated transaminase levels and lymphopenia. In practice, midostaurin can be offered to patients aged less than 60 years with careful monitoring of adverse effects. It is important to report these adverse effects.

RYDAPT° - midostaurin soft capsules

- 25 mg of midostaurin per soft capsule

- antineoplastic; inhibitor of tyrosine kinases including FLT3 and KIT

- Indication: “in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive”. [EU centralised procedure – orphan drug].